<DOC>
	<DOCNO>NCT00350207</DOCNO>
	<brief_summary>This 16 week multicentre , multinational , randomised , double-blind , double-dummy , placebo-controlled , parallel group study evaluate long-term efficacy safety tiotropium compare salmeterol moderate persistent asthmatic ( GINA step 3 ) patient homozygous arginine 16th amino acid position beta-adrenergic receptor ( ADRB2 ) . Following initial 4-week run-in period salmeterol MDI patient randomise 16 week double-blind treatment period receive either tiotropium daily administer Respimat inhaler salmeterol twice daily administer hydrofluoro-alkane Metered Dose Inhaler ( MDI ) , placebo twice daily . After 16 week treatment period patient receive salmeterol MDI twice daily four week . The patient perform daily morning evening peak flow ( PEF ) Forced Expiratory Volume First Second ( FEV1 ) measurements electronic peak flow meter throughout study . Daily data asthma control use rescue medication record use electronic diary include electronic peak flow meter . On study visit Mini-Asthma Quality Life Questionnaire ( Elizabeth Juniper ) administer , pulse blood pressure pre-dose pulmonary function test ( FEV1 Forced Vital Capacity ) perform .</brief_summary>
	<brief_title>Efficacy Safety Tiotropium Salmeterol Moderate Persistent Asthma Patients Homozygous B16-Arg/Arg</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Inclusion_Criteria : 1 . Patients homozygous arginine 16th amino acid position beta2 adrenergic receptor ( B16 Arg/Arg ) 2 . All patient must sign date Informed Consent Form study prior participation trial 3 . Male female outpatient least 18 year age , old 65 year 4 . Patients must document history asthma 5 . Patients must current nonsmoker exsmokers cigarette smoke history &lt; 10 packyears 6 . Patients must maintenance treatment inhaled corticosteroid total daily dose 400 1000 mcg budesonide equivalent Exclusion_Criteria : 1 . Patients significant disease asthma 2 . Patients recent history ( i.e. , six month less ) myocardial infarction 3 . Patients hospitalized heart failure ( New York Heart Association class III IV ) within past year 4 . Patients unstable life threaten cardiac arrhythmia cardiac arrhythmia require intervention change drug therapy within past year 5 . Patients malignancy patient undergone resection , radiation therapy chemotherapy within last five year . Patients treat basal cell carcinoma allow . 6 . Patients diagnosis chronic obstructive pulmonary disease ( COPD ) 7 . Patients history life threaten pulmonary obstruction , history cystic fibrosis clinically evident bronchiectasis 8 . Patients know active tuberculosis 9 . Patients undergone thoracotomy pulmonary resection . 10 . Patients complete pulmonary rehabilitation program six week prior visit 1 patient currently pulmonary rehabilitation program maintain throughout duration study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>